Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2018 16:03 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports First Quarter 2018 Financial Results

CAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
April 11, 2018 16:05 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia

CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
April 02, 2018 16:09 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

CAMBRIDGE, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
March 28, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
March 19, 2018 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors

CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other...
December 11, 2017 16:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11,...
November 09, 2017 16:18 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Third Quarter 2017 Financial Results

Company continues to advance clinical trials of lead product candidate ALRN-6924 in PTCL and AML/MDS Two abstracts selected for oral presentations at American Society of Hematology Annual Meeting,...
November 01, 2017 09:19 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other...
September 19, 2017 07:00 ET | Source: Aileron Therapeutics

Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes

CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other...
August 24, 2017 07:00 ET | Source: Aileron Therapeutics

Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting

CAMBRIDGE, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right